Future therapeutic treatment of COPD: Struggle between oxidants and cytokines

International Journal of COPD

Volumn 2, Issue 3, 2007, Pages 205-228

  de Boer, Willem I ^a   Yao, Hongwei ^b   Rahman, Irfan ^b  

^a Netherlands Asthma Foundation   (Netherlands)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Antagonists; Antioxidants; COPD; Cytokines; Inflammation; Remodeling

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; 5,6,7,13 TETRAHYDRO 12 (3 HYDROXYPROPYL) 9 ISOPROPOXYMETHYLINDENO[2,1 A]PYRROLO[3,4 C]CARBAZOL 5(12H) ONE DIMETHYLGLYCINE ESTER; ACETYLCYSTEINE; ADALIMUMAB; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA CAROTENE; BEVACIZUMAB; BORTEZOMIB; CILOMILAST; CORTICOSTEROID; CYTOKINE; ELASTASE INHIBITOR; ERDOSTEINE; ETANERCEPT; HISTONE DEACETYLASE INHIBITOR; INFLIXIMAB; LACTACYSTIN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NSC 11118; OXIDIZING AGENT; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; ROFLUMILAST; SB 681323; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ASTHMA; BRONCHIECTASIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CYSTIC FIBROSIS; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TARGETING; HUMAN; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; LUNG EMPHYSEMA; MUCOLYSIS; NAUSEA; NEUTROPHIL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; QUALITY OF LIFE; RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOKING; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTI-INFLAMMATORY AGENTS; CYTOKINES; DIETARY SUPPLEMENTS; HUMANS; OXIDANTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS;

EID: 36148988782     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (234)

1. Abdelhady H, Flores R, Tan H, et al. 2005. Infliximab treatment for chronic obstructive pulmonary disease (COPD) - a pilot study. Proc Am Thorac Soc, 2:A133.
2. Adams J, Palombella VJ, Sausville EA, et al, Proteasome inhibitors. 1999. a novel class of potent and effective antitumor agents. Cancer Res, 59:2615-22.
3. Aghdassi E, Royall D, Allard JP. 1999. Oxidative stress in smokers supplemented with vitamin C. Int J Vitam Nutr Res, 69:45-51.
4. Agusti AG, Noguera A, Sauleda J, et al. 2003. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J, 21:347-60.
5. Antonicelli F, Parmentier M, Drost EM, et al. 2002. Nacystelyn inhibits oxidant-mediated interleukin-8 expression and NF-kappaB nuclear binding in alveolar epithelial cells. Free Radic Biol Med, 32:492-502.
6. Auten RL, Richardson RM, White JR, et al. 2001. Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J Pharmacol Exp Ther, 299:90-5.
7. Baldwin AS Jr. 1996. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol, 14:649-83.
8. Bals R, Hiemstra PS. 2006. Antimicrobial peptides in COPD - basic biology and therapeutic applications. Curr Drug Targets, 7:743-50.
9. Barber R, Baillie GS, Bergmann R, et al. 2004. Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol, 287:L332-43.
10. Barnes PJ, Shapiro SD, Pauwels RA. 2003. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J, 22:672-88.
11. Barnes PJ, Stockley RA. 2005. COPD: current therapeutic interventions and future approaches. Eur Respir J, 25:1084-106.
12. Barnes PJ. 2006. Corticosteroid effects on cell signalling. Eur Respir J, 27:413-26.
13. Basu-Modak S, Luscher P, Tyrrell RM. 1996. Lipid metabolite involvement in the activation of the human heme oxygenase-1 gene. Free Radic Biol Med, 20:887-97.
14. Baxter A, Cooper A, Kinchin E, et al. 2006. Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists. Bioorg Med Chem Lett, 16:960-3.
15. Berry MA, Hargadon B, Shelley M, et al. 2006. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med, 354:697-708.
16. Boots AW, Haenen GF, Bast A. 2003. Oxidant metabolism in chronic obstructive pulmonary disease. Eur Respir J Suppl, 46:14s-27s.
17. Bracke KR, D'Hulst AI, Maes T, et al. 2006. Cigarette smoke-induced pulmonary inflammation and emphysema are attenuated in CCR6-deficient mice. J Immunol, 177:4350-9.
18. Briata P, Forcales SV, Ponassi M, et al. 2005. p38-dependent phosphorylation of the mRNA decay-promoting factor KSRP controls the stability of select myogenic transcripts. Mol Cell, 20:891-903.
19. Bridgeman MM, Marsden M, Selby C, et al. 1994. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax, 49:670-5.
20. Bridges AB, Scott NA, Parry GJ, et al. 1993. Age, sex, cigarette smoking and indices of free radical activity in healthy humans. Eur J Med, 2:205-8.
21. Brightling CE, McKenna S, Hargadon B, et al. 2005. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease. Thorax, 60:193-8.
22. Britton JR, Pavord ID, Richards KA, et al. 1995. Dietary antioxidant vitamin intake and lung function in the general population. Am J Respir Crit Care Med, 151:13 83-7.
23. Brodmerkel CM, Huber R, Covington M, et al. 2005. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol, 175:5370-8.
24. Bruce C, Thomas PS. 2005. The effect of marimastat, a metalloprotease inMbitor, on allergen-induced asthmatic hyper-reactivity. Toxicol Appl Pharmacol, 205:126-32.
25. Butora G, Morriello GJ, Kothandaraman S, et al. 2006. 4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties. Bioorg Med Chem Lett, 16:4715-22.
26. Butterworth M, Upshall DG, Hobbs M, et al. 1993. Elevation of cysteine and replenishment of glutathione in rat lung slices by cysteme isopropylester and other cysteine precursors. Biochem Pharmacol, 45:1769-74.
27. Cantor JO, Cerreta JM, Armand G, et al. 1997. Further investigation of the use of intratracheally administered hyaluronic acid to ameliorate elastase-induced emphysema. Exp Lung Res, 23:229-44.
28. Cantor JO, Shteyngart B, Cerreta JM, et al. 2000. The effect of hyaluronan on elastic fiber injury in vitro and elastase-induced airspace enlargement in vivo. Proc Soc Exp Biol Med, 225:65-71.
29. Cantor JO, Cerreta JM, Ochoa M, et al. 2005. Aerosolized hyaluronan limits airspace enlargement in a mouse model of cigarette smoke-induced pulmonary emphysema. Exp Lung Res, 31:417-30.
30. Castro AC, Dang LC, Soucy F, et al. 2003. Novel IKK inhibitors: beta-carbolines. Bioorg Med Chem Lett, 13:2419-22.
31. Celedon JC, Lange C, Raby BA, et al. 2004. The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet, 13:1649-56.
32. Chabrier PE, Auguet M, Spinnewyn B, et al. 1999. BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy. Proc Natl Acad Sci U S A, 96:10824-9.
33. Chanez P, Vignola AM, O'Shaugnessy T, et al. 1997. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med, 155:1529-34.
34. Cheng J, Diaz Encarnacion MM, Warner GM, et al. 2005. TGF-beta1 stimulates monocyte chemoattractant protein-1 expression in mesangial cells through a phosphodiesterase isoenzyme 4-dependent process. Am J Physiol Cell Physiol, 289:C959-70.
35. Choi AM, Elbon CL, Bruce SA, et al. 1994. Messenger RNA levels of lung extracellular matrix proteins during ozone exposure. Lung, 172:15-30.
36. Chughtai B, O'Riordan TG. 2004. Potential role of inhibitors of neutrophil elastase in treating diseases of the airway. J Aerosol Med, 17:289-98.
37. Chung KF. 2006. Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug Targets, 7:675-81.
38. Churg A, Wang RD, Xje C, et al. 2003. alpha-] -Antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. Am J Respir Crit Care Med, 168:199-207.
39. Churg A, Tai H, Coulthard T, et al. 2006. Cigarette smoke drives small airway remodeling by induction of growth factors in the airway wall. Am J Respir Crit Care Med, 174:1327-34.
40. Corradi M, Rubinstein I, Andreoli I, et al. 2003. Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 167:1380-6.
41. Cosio BG, Tsaprouni L, Ito K, et al. 2004. Theophylline restores histone deacetylase activity and steroid responses in COPI) macrophages. J Exp Med, 200:689-95.
42. Cotgreave IA. 1997. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol, 38:205-27.
43. Cross CE, O'Neill CA, Reznick AZ, et al. 1993. Cigarette smoke oxidation of human plasma constituents. Ann N Y Acad Sci, 686:72-89; discussion 89-90.
44. Cross CE, van der Vliet A, O'Neill CA, et al. 1994. Oxidants, antioxidants, and respiratory tract lining fluids. Environ Health Perspect, 102 Suppl 10:185-91.
45. Culpitt SV, Rogers DF, Shah P, et al. 2003. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 167:24-31.
46. Culpitt SV, Rogers DF, Traves SL, et al. 2005. Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. Respir Med, 99:703-10.
47. De Benedetto F, Aceto A, Dragani B, et al. 2005. Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther, 18:41-7.
48. De Boer WI, van Schadewijk A, Sont JK, et al. 1998. Transforming growth factor beta1 and recruitment of macrophages and mast cells in airways in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 158:1951-7.
49. De Boer WI. 2002. Cytokines and therapy in COPD: a promising combination? Chest, 121:209S-218S.
50. de Boer WI. 2005. Perspectives for cytokine antagonist therapy in COPD. Drug Discov Today, 10:93-106.
51. De Boer WI, Hau CM, van Schadewijk A, et al. 2006. Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. Am J Clin Pathol, 125:184-92.
52. De Boer WI, Alagappan V& Sharma HS. 2007. Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy. Cell Biochem Biophys, 47:131-48.
53. Dean JL, Sully G, Clark AR, et al. 2004. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal, 16:1113-21.
54. Decramer M, Dekhuijzen PN, Troosters T, et al. 2001. The bronchitis randomized on NAC cost-utility study (BRONCUS): hypothesis and design BRONCUS-trial Committee. Eur Respir J, 17:329-36.
55. Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. 2005. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet, 365:1552-60.
56. Dekhuijzen PN. 2004. Antioxidant properties of N-acetylcysteme: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J, 23:629-36.
57. Delhase M, Li N, Karin M. 2000. Kinase regulation in inflammatory response. Nature, 406:367-8.
58. Demedts IK, Morel-Montero A, Lebecque S, et al. 2006. Elevated MMP-12 protein levels in induced sputum from patients with COPD. Thorax, 61:196-201.
59. Dentener MA, Vemooy JH, Hendriks S, et al. 2005. Enhanced levels of hyaluronan in lungs of patients with COPD: relationship with lung ftmction and local inflammation. Thorax, 60:114-19.
60. DenteneT MA, Louis R, Cloots RH, et al. 2006. Differences in local versus systemic TNFalpha production in COPD: inhibitory effect of hyaluronan on LPS induced blood cell TNFalpha release. Thorax, 61:478-84.
61. Devalaraja RM, Nanney LB, Du J, et al. 2000. Delayed wound healing in CXCR2 knockout once. J Invest Dermatol, 115:234-44.
62. Di Stefano A, Capelli A, Luguardi M, et al. 2001. Decreased T lymphocyte infiltration in bronchial biopsies of subjects with severe chronic obstructive pulmonary disease. Clin Exp Allergy, 31:893-902.
63. Dillon TJ, Walsh RL, Scicchitano R, et al. 1992. Plasma elastin-derived peptide levels in normal adults, children, and emphysematous subjects. Physiologic and computed torriographic scan correlates. Am Rev Respir Dis, 146:1143-8.
64. Dueholin M, Nielsen C, Thorshauge H, et al. 1992. N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study. Respir Med, 86:89-92.
65. Dwyer MP, Yu Y, Chao J, et al. 2006. Discovery of 2-Hydroxy-N, N-dimethyl-3-{2- (R)-1-(5-methylfuran- 2-yl)propyl]amino]-3, 4-dioxocyclobut-1 -enylamino}benzamide (SCH 527123): A Potent, Orally Bioavailable CXCR2/CXCRl Receptor Antagonist. J Med Chem, 49:7603-6.
66. Edwards PD, Andisik DW, Bryant CA, et al. 1997. Discovery and biological activity of orally active peptidyl trifluoromethyl ketone inhibitors of human neutrophil elastase. J Med Chem, 40:1876-85.
67. Ekberg-Jansson A, Larson M, MacNee W, et al. 1999. N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. Eur Respir J, 13:829-34.
68. Erin EM, Leaker BR, Nicholson GC, et al. 2006. The effects of a monoclonal antibody directed against rumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med, 174:753-62.
69. Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat Med, 9:669-76.
70. Ferry G, Lonchampt M, Pennel L, et al. 1997. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett, 402:111-15.
71. Fitzgerald MF, Spicer D, Ma JY, et al. 2006. Efficacy of the p38 MAP Kinase Inhibitor, SD-282, in an Inflammatory Model of COPD in A/J Mice. Proc Am Thorac Soc, 3:A850.
72. Gamble E, Grootendorst DC, Brightling CE, et al. 2003. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 168:976-82.
73. Gan WQ, Man SF, Sin DD. 2005. Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Palm Med, 5:3.
74. Gartlehner G, Hansen RA, Carson SS, et al. 2006. Efficacy and safety of inhaled corticosteroids inpatients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med, 4:253-62.
75. Gerrits CM, Herings RM, Leufkens HG, et al. 2003. N-acetyleysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J, 21:795-8.
76. Ghosh S, May MJ, Kopp EB. 1998. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol, 16:225-60.
77. Gilks CB, Price K, Wright JL, et al. 1998. Antioxidant gene expression in rat lung after exposure to cigarette smoke. Am J Pathol, 152:269-78.
78. Gillissen A, Jaworska M, Orth M, et al. 1997. Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Respir Med, 91:159-68.
79. Gosman MM, Boezen HM, van Diemen CC, et al. 2006. A disintegrin and metalloproteinase 33 and chronic obstructive pulmonary disease pathophysiology. Thorax, 62:242-7.
80. Gosman MM, Willemse BW, Jansen DF, et al. 2006. Increased number of B-cells in bronchial biopsies in COPD. Eur Respir J, 27:60-A.
81. Grashoff WF, Sont JK, Sterk PJ, et al. 1997. Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am J Pathol, 151:1785-90.
82. Grievink L, Smit HA, Ocke MC, et al. 1998. Dietary intake of antioxidant (pro)-vitamins, respiratory symptoms and pulmonary function: the MORGEN study. Thorax, 53:166-71.
83. Grootendorst DC, Gauw SA, Sterk PJ. 2005. Treatment with PDE4 inhibitor roflumilast reduces sputum neutrophil and eosinophil numbers in patients with COPD. Proc Am Thoracic Soc, 2:A543.
84. Guest TM, Vlastos G, Alarrieddine FM, et al. 2006. Mechanoregulation of monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Antioxid Redox Signal, 8:1461-71.
85. Guidot DM, Brown LA. 2000. Mitochondrial glutathione replacement restores surfactant synthesis and secretion in alveolar epithelial cells of ethanol-fed rats. Alcohol Clin Exp Res, 24:1070-6.
86. Habib MP, Tank LJ, Lane LC, et al. 1999. Effect of vitamin E on exhaled ethane in cigarette smokers. Chest, 115:684-90.
87. Haddad EB, BirrelIM, McCluskie K, et al. 2001. Role of p38 MAPkmase in LPS-induced airway inflammation in the rat. Br J Pharmacol, 132:1715-24.
88. Haringman JJ, Gerlag DM, Smeets TJ, et al. 2006. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum, 54:2387-92.
89. Harju T, Kaarteenaho-Wiik R, Soini Y, et al. 2002. Diminished immunoreactivity of gamma-glutamylcysteine synthetase in the airways of smokers' lung. Am J Respir Crit Care Med, 166:754-9.
90. Harrison DJ, Cantlay AM, Rae F, et al. 1997. Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer. Hum Exp Toxicol, 16:356-60.
91. Hautamaki RD, Kobayashi DK, Senior RM, et al. 1997. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science, 277:2002-4.
92. Hayasaki T, Kaikita K, Okuma T, et al. 2006. CC chemokine receptor-2 deficiency attenuates oxidative stress and infarct size caused by myocardial ischemia-reperfusion in mice. Circ J, 70:342-51.
93. Hitti E, Iakovleva T, Brook M, et al. 2006. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetrapTolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol, 26:2399-407.
94. Ho KK, Auld DS, Bohnstedt AC, et al. 2006. Imidazolylpyrimidine based CXCR2 chemokine receptor antagonists. Bioorg Med Chem Lett, 16:2724-8.
95. Hogg JC. 2004. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet, 364:709-21.
96. Holmes-McNary M, Baldwin AS Jr. 2000. Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res, 60:3477-83.
97. Hoogendoorn M, FeenstTa TL, Rutten-van Molken MP. 2006. [Projections of future resource use and the costs of asthma and COPD in the Netherlands]. Ned Tijdschr Geneeskd, 150:1243-50.
98. Howarth PH, Babu KS, Arshad HS, et al. 2005. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax, 60:1012-18.
99. Huang SM, Wu CH, Yen GC. 2006. Effects of flavonoids on the expression of the pro-inflammatory response in human monocytes induced by ligation of the receptor for AGEs. Mol Nutr Food Res, 50:1129-39.
100. Hynninen KM, Breitve MH, Wiborg AB, et al. 2005. Psychological characteristics of patients with chronic obstructive pulmonary disease: a review. J Psychosom Res, 59:429-43.
101. Ito K, Lim S, Caramori G, et al. 2001. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. Faseb J, 15:1110-12.
102. Ito K, Ito M, Elliott WM, et al. 2005. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med, 352:1967-76.
103. Jazrawi E, Cosio BG, Barnes PJ, et al. 2003. Inhibition of IKK2 and JNK differentially regulates GM-CSF and IL-8 release in epithelial cells and alveolar macrophages. Am J Respir Crit Care Med, 167:A798.
104. Johnson GL, Lapadat R. 2002. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science, 298:1911-12.
105. Jones PW 2006. Health status: what does it mean for payers and patients? Proc Am Thorac Soc, 3:222-6.
106. Joos L, He JQ, Shepherdson MB, et al. 2002. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet, 11:569-76.
107. Karimi K, Sarir H, Mortaz E, et al. 2006. Toll-like receptor-4 mediates cigarette smoke-induced cytokine production by human macrophages. Respir Res, 7:66.
108. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, et al. 2000. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest, 106:1311-19.
109. Kasielski M, Nowak D. 2001. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med, 95:448-56.
110. Kassim SY, Fu X, Liles WC, et al. 2005. NADPH oxidase restrains the matrix metalloprotemase activity of macrophages. J Biol Chem, 280:30201-5.
111. Keatings VM, Cave SJ, Henry MJ, et al. 2000. A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD. Chest, 118:971-5.
112. Kirkham PA, Spooner G, Rahman I, et al. 2004. Macrophage phagocytosis of apoptotic neutrophils is compromised by matrix proteins modified by cigarette smoke and lipid peroxidation products. Biochem Biophys Res Commun, 318:32-7.
113. Koechlin C, Couillard A, Cristol JP, et al. 2004. Does systemic inflammation trigger local exercise-induced oxidative stress in COPD? Eur Respir J, 23:538-44.
114. Koethe SM, Kuhrunuench JR, Becker CG. 2000. Neutrophil priming by cigarette smoke condensate and a tobacco anti-idiotypic antibody. Am J Pathol, 157:1735-43.
115. Kondo T, Tagami S, Yoshioka A, et al. 1994. Current smoking of elderly men reduces antioxidants in alveolar macrophages. Am J Respir Crit Care Med, 149:178-82.
116. Kranenburg AR, De Boer WI, Van Krieken JH, et al. 2002. Enhanced expression of fibroblast growth factors and receptor FGFR-1 during vascular remodeling in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol, 27:51, 7-25.
117. Kranenburg AR, de Boer WI, Alagappan VK, et al. 2005. Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease. Thorax, 60:106-13.
118. Kranenburg AR, Willems-Widyastuti A, Moori WJ, et al. 2006. Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease. Am J Clin Pathol, 126:725-35.
119. Kucukaycan M, Van Krugten M, Pennings HJ, et al. 2002. Tumor necrosis factor-alpha +489G/A gene polymorphism is associated with chronic obstructive pulmonary disease. Respir Res, 3:29.
120. Kumagai T, Matsukawa N, Kaneko Y, et al. 2004. A lipid peroxidation-derived inflammatory mediator: identification of 4-hydroxy-2-nonenal as a potential inducer of cyclooxygenase-2 in macrophages. J Biol Chem, 279:48389-96.
121. Kumar S, Boehm J, Lee JC. 2003. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov, 2:717-26.
122. Lang MR, Fiaux GW, Gillooly M, et al. 1994. Collagen content of alveolar wall tissue in emphysematous and non-emphysematous lungs. Thorax, 49:319-26.
123. Langen RC, Kom SH, Wouters EF. 2003. ROS in the local and systemic pathogenesis of COPD. Free Radic Biol Med, 35:226-35.
124. Lee JC, Kassis S, Kumar S, et al. 1999. p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials. Pharmacol Ther, 82:389-97.
125. Leff AR. 2006. Tissue remodeling and repair mechanisms in chronic obstructive pulmonary disease. Proc Am Thorac Soc, 3:734-6.
126. Liao L, Ning Q, Li Y, et al. 2006. CXCR2 blockade reduces radical formation in hyperoxia-exposed newborn rat lung. Pediatr Res, 60:299-303.
127. Lindberg A, Bjerg-Backlund A, Ronmark E, et al. 2006. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med, 100:264-72.
128. Lindholt JS, Jorgensen B, Shi GP, et al. 2003. Relationships between activators and inhibitors of plasminogen, and the progression of small abdominal aortic aneurysms. Eur J Pasc Endovasc Surg, 25:546-51.
129. Loke WM, Proudfoot JM, McKinley AJ, et al. 2006. Augmentation ofmonocyte intracellular ascorbate in vitro protects cells from oxidative damage and inflammatory responses. Biochem Biophys Res Commun, 345:1039-43.
130. Lykkesfeldt J, Christen S, Wallock LM, et al. 2000. Ascorbate is depleted by smoking and repleted by moderate supplementation: a study in male smokers and nonsmokers with matched dietary antioxidant intakes. Am J Clin Nutr, 71:530-6.
131. +T cells are required for inflammation and destruction in cigarette smoke-induced emphysema in mice. J Immunol, 178:8090-6.
132. Martin-Mosquero C, Peces-Barba G, Rubio ML, et al. 2006. Increased collagen deposition correlated with lung destruction in human emphysema. Histo/Histopathol, 21:823-8.
133. Marwick JA, Kirkham PA, Stevenson CS, et al. 2004. Cigarette smoke alters chromatin remodeling and induces proinflammatory genes in rat lungs. Am J Respir Cell Mol Biol, 31:63 3-42.
134. Marwick JA, Stevenson CS, Giddings J, et al. 2006. Cigarette smoke disrupts VEGF165-VEGFR-2 receptor signaling complex in rat lungs and patients with COPD: morphological impact of VEGFR-2 inhibition. Am J Physiol Lung Cell Mol Physiol, 290:L897-908.
135. Matsuoka H, Arai T, Mori M, et al. 2002. A p38 MAPK inhibitor, FR- 167653, ameliorates murine bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol, 283:L103-12.
136. McCusker K, Hoidal J. 1990. Selective increase of antioxidant enzyme activity in the alveolar macrophages from cigarette smokers and smoke-exposed hamsters. Am Rev Respir Dis, 141:678-82.
137. Meja KK, Seldon PM, Nasuhara Y, et al. 2000. p38 MAP kinase and MKK- I co-operate in the generation of GM-CSF from LPS-stimulated human monocytes by an NF-kappa B-independent mechanism. Br J Pharmacol, 131:1143-53.
138. Menezes AM, Perez-Padilla R, Jardirn JR, et al. 2005. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet, 366:1875-81.
139. Mezzetti A, Lapenna D, Pierdomenico SD, et al. 1995. Vitamins E, C and lipid peroxidation in plasma and arterial tissue of smokers and non-smokers. Atherosclerosis, 112:91-9.
140. Milatovic S, Nanney LB, Yu Y, et al. 2003. Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Wound Repair Regen, 11:213-19.
141. Monteleone G, Kumberova A, Croft NM, et al. 2001. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest, 108:601-9.
142. Moodie FM, Marwick JA, Anderson CS, et al. 2004. Oxidative stress and cigarette smoke alter chromatin remodeling but differentially regulate NF-kappaB activation and proinflammatory cytokine release in alveolar epithelial cells. Faseb J, 18: 1997-9.
143. Moretti M, Bottrighi P, Dallari R, et al. 2004. The effect of long-term treatment with erdosteine on chronic obstructive pulmonary disease: the EQUALIFE Study. Drugs Exp Clin Res, 30:143-52.
144. Morquette B, Shi Q, Lavigne P, et al. 2006. Production of lipid peroxidation products in osteoarthritic tissues: new evidence linking 4-hydroxynonenal to cartilage degradation. Arthritis Rheum, 54:271-81.
145. Morrison D, Rahman 1, Lannan S, et al. 1999. Epithelial permeability, inflammation, and oxidant stress in the air spaces of smokers. Am J Respir Crit Care Med, 159:473-79.
146. Muller K, Hardwick SJ, Marchant CE, et al. 1996. Cytotoxic and chemotactic potencies of several aldehydic components of oxidised low density lipoprotein for human monocyte-macrophages. FEBS Lett, 388:165-8.
147. Nasuhara Y, Adcock IM, Catley M, et al. 1999. Differential IkappaB kinase activation and IkappaBalpha degradation by interleukin-1 beta and tumor necrosis factor-alpha in human U937 monocytic cells Evidence for additional regulatory steps in kappaB-dependent transcription. J Biol Chem, 274:19965-72.
148. Neurohr C, Lenz AG, Ding I, et al. 2003. Glutamate-cysteine ligase modulatory subunit in BAL alveolar macrophages of healthy smokers. Eur Respir J, 22:82-7.
149. Nicholson GC, Tennant RC, Carpenter DC, et al. 2007. A novel flow cytometric assay of human whole blood neutrophil and monocyte CD11b levels: upregulation by chemokines is related to receptor expression, comparison with neutrophil shape change, and effects of a chemokine receptor (CXCR2) antagonist. Pulm Pharmacol Ther, 20:52-9.
150. Nishi T, Maier CM, Hayashi T, et al. 2005. Superoxide dismutase 1 overexpression reduces MCP-1 and MIP-1 alpha expression after transient focal cerebral ischemia. J Cereb Blood Flow Metab, 25:1312-24.
151. Nishikawa M, Kakemizu N, Ito T, et al. 1999. Superoxide mediates cigarette smoke-induced infiltration of neutrophils into the airways through nuclear factor-kappaB activation and IL-8 mRNA expression in guinea pigs in vivo. Am J Respir Cell Mol Biol, 20:189-98.
152. Noguera A, Busquets X, Sauleda, J, et al. 1998. Expression of adhesion molecules and G proteins in circulating neutrophils in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 158:1664-8.
153. Ogryzko VV, Schiltz RL, Russanova. V, et al. 1996. The transcriptional coactivaters p300 and CBP are histone acetyltransferases. Cell, 87:953-9.
154. Okada Y, Watanabe S, Nakanishi I, et al. 1988. Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine protemases. FEBS Lett, 229:157-60.
155. Papi A, Romagnoli M, Baraldo S, et al. 2000. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 162:1773-7.
156. Parasrampuria DA, de Boer P, Desai-Krieger D, et al. 2003. Single-dose pharmacokinetics and pharmacodynamics of RWJ 67657, a specific p3 8 mitogen-activated protein kinase inhibitor: a first-in-human study. J Clin Pharmacol, 43:406-13.
157. Parola M, Pinzani M, Casini A, et al. 1993. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (1) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun, 194:1044-50.
158. Pasternak A, Marino D, Vicario PP, et al. 2006. Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists. J Med Chem, 49:4801-4.
159. Pauwels RA, Rabe KF. 2004. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet, 364:613-20.
160. Pemberton PA, Kobayashi D, Wilk BJ, et al. 2006. Inhaled recombinant alpha 1-antitrypsin ameliorates cigarette smoke-induced emphysema in the mouse. Copd, 3:101-8.
161. Petruzzelli S, Hietanen E, Bartsch H, et al. 1990. Pulmonary lipid peroxidation in cigarette smokers and lung cancer patients. Chest, 98:930-5.
162. Pizzichini E, Pizzichini MM, Gibson P, et al. 1998. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis: Am J Respir Crit Care Med, 158:1511-17.
163. Poole PJ, Black PN. 2006. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 3:CD001287.
164. Postma DS, Timens W. 2006. Remodeling in asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc, 3:434-9.
165. Rabe KF, Bateman ED, O'Donnell D, et al. 2005. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 366:563-71.
166. Rahman I, Adcock IM. 2006. Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J, 28:219-42.
167. Rahman I, MacNee W 1996a. Oxidant/antioxidant imbalance in smokers and chronic obstructive pulmonary disease. Thorax, 51:348-50.
168. Rahman I, MacNee W 1996b. Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med, 21:669-81.
169. Rahman I, MacNee W. 1998. Role of transcription factors in inflammatory lung diseases. Thorax, 53:601-12.
170. Rahman I, MacNee W 1999. Lung glutathione and oxidative stress: implications in cigarette smoke-induced airway disease. Am J Physiol, 277: L1067-88.
171. Rahman I, MacNee W 2000a. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J, 16:534-54.
172. Rahman I, MacNee W 2000b. Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. Free Radic Biol Med, 28:1405-20.
173. Rahman I, Morrison D, Donaldson K, et al. 1996. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med, 154:1055-60.
174. Rahman I, Skwarska E, MacNee W 1997. Attenuation of oxidant/antioxidant imbalance during treatment of exacerbations of chronic obstructive pulmonary disease. Thorax, 52:565-8.
175. Rahman I, Gilmour PS, Jimenez LA, et al. 2002. Oxidative stress and TNF-alpha induce histone acetylation and NF-kappaB/AP-1 activation in alveolar epithelial cells: potential mechanism in gene transcription in lung inflammation. Mol Cell Biochem, 234-5:239-48.
176. Rahman I, van Schadewijk AA, Crowther AJ, et al. 2002. 4-Hydroxy-2-nonenal, a specific lipid peroxidation product, is elevated in lungs of patients with chronic obstructive pulmonary disease. Am JRespir Crit Care Med, 166:490-5.
177. Rahman I, Marwick J, Kirkham P. 2004. Redox modulation of chromatin remodeling: impact on histone acetylation and deacetylation, NF-kappaB and pro-inflammatory gene expression. Biochem Pharmacol, 68:1255-67.
178. Rajagopalan S, Meng XP, Ramasamy S, et al. 1996., Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest, 98:2572-9.
179. Rasmussen JB, Glennow C. 1988. Reduction in days of illness after
180. Rautalahti M, Virtamo J, Haukka J, et al. 1997. The effect of alpha-tocopherol and beta-carotene supplementation on COPI) symptoms. Am J Respir Crit Care Med, 156:1447-52.
181. Ray P, Devaux Y, Stolz DB, et al. 2003. Inducible expression of keratinocyte growth factor (KGF) in mice inhibits lung epithelial cell death induced by hyperoxia. Proc Natl Acad Sci U S A, 100:6098-103.
182. Rennard SI, Fogarty C, Kelsen S, et al; for the COPI) Investigators. 2007. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 175:926-34.
183. Rennard SI, Schachter N, Strck M, et al. 2006. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest, 129:56-66.
184. Rennekampff HO, Hansbrough JF, Woods V Jr, et al. 1997. Role of melanoma growth stirmilatory activity (MGSA/gro) on keratinocyte function in wound healing. Arch Dermatol Res, 289:204-12.
185. Rennekampff HO, Hansbrough JF, Kiessig V, et al. 2000. Bioactive interleukin-8 is expressed in wounds and enhances wound healing. J Surg Res, 93:41-54.
186. Repine JE, Bast A, Lankhorst 1. 1997. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med, 156:341-57.
187. Rolin S, Masereel B, Dogne JM. 2006. Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol, 533:89-100.
188. Roth SY, Denu JM, Allis CD. 2001. Histone acetyltransferases. Annu Rev Biochem, 70:81-120.
189. Russell RE, Culpitt SV, DeMatos C, et al. 2002. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol, 26:602-9.
190. Rusznak C, Mills PR, Devalia JL, et al. 2000. Effect of cigarette smoke on the permeability and IL-1 beta and sICAM-1 release from cultured human bronchial epithelial cells of never-smokers, smokers, and patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol, 23:530-6.
191. Sadowska AM, Manuel YKB, De Backer WA. 2007. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther, 20:9-22.
192. Saetta M, Baraldo S, Corbino L, et al. 1999. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 160:711-17.
193. Saika S, Ikeda K, Yamanaka O, et al. 2005. Expression of Smad7 in mouse eyes accelerates healing of comeal tissue after exposure to alkali. Am J Pathol, 166:1405-18.
194. Sandford AJ, Chagani T, Weir TD, et al. 2001. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med, 163:469-73.
195. Sargeant LA, Jaeckel A, Wareham NJ. 2000. Interaction of vitamin C with the relation between smoking and obstructive airways disease in EPIC Norfolk. European Prospective Investigation into Cancer and Nutrition. Eur Respir J, 16:397-403.
196. Schaur RJ, Dussing G, Kink E, et al. 1994. The lipid peroxidation product 4-hydroxynonenal is formed by - and is able to attract - rat neutrophils in vivo. Free Radic Res, 20:365-73.
197. Scott DA, Stapleton JA, Wilson RF, et al. 2000. Dramatic decline in circulating intercellular adhesion molecule-1 concentration on quitting tobacco smoking. Blood Cells Mol Dis, 26:255-8.
198. Shahar E, Boland LL, Folsom AR, et al. 1999. Docosahexaenoic acid and smoking-related chronic obstructive pulmonary disease. The Atherosclerosis Risk in Communities Study Investigators. Am J Respir Crit Care Med, 159:1780-5.
199. Shapiro SD, Goldstein NM, Houghton AM, et al. 2003. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol, 163:2329-35.
200. Shen Y, Rattan V, Sultana C, et al. 1996. Cigarette smoke condensate-induced adhesion molecule expression and transendothelial migration of monocytes. Am J Physiol, 270:H1624-33.
201. Sin DD, Anthonisen NR, Soriano JB, et al. 2006. Mortality in COPD: role of comorbidities. Eur Respir J, 28:1245-57.
202. Smith KR, Uyeminami DL, Kodavanti UP, et al. 2002. Inhibition of tobacco smoke-induced lung inflammation by a catalytic antioxidant. Free Radic Biol Med, 33:1106-14.
203. Snider GL. 1989. Chronic obstructive pulmonary disease: risk factors, pathophysiology and pathogenesis. Annu Rev Med, 40:411-29.
204. Springer J, Scholz FR, Peiser C, et al. 2004. SMAD-signaling in chronic obstructive pulmonary disease: transcriptional down-regulation of inhibitory SMAD 6 and 7 by cigarette smoke. Biol Chem, 385:649-53.
205. Spycher SE, Tabataba-Vakili S, O'Donnell VB, et al. 1997. Aldose reductase induction: a novel response to oxidative stress of smooth muscle cells. Faseb J, 11:181-8.
206. Steinberg FM, Chait A. 1998. Antioxidant vitamin supplementation and lipid peroxidation in smokers. Am J Clin Nutr, 68:319-27.
207. Steinerova A, Racek J, Stozicky F, et al. 2001. Antibodies against oxidized LDL - theory and clinical use. Physiol Res, 50:131-41.
208. Stey C, Steurer J, Bachmann S, et al. 2000. The effect of oral N-acetyl-cysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J, 16:253-62.
209. Stone PJ, Gottlieb DJ, O'Connor GT, et al. 1995. Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 151:952-9.
210. Sullivan AK, Simonian PL, Falta MT, et al. 2005. Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med, 172:590-6.
211. Takizawa H, Tanaka M, Takami K, et al. 2001. Increased expression of transforming growth factor-beta1 in small airway epithelium from tobacco smokers and patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med, 163:1476-83.
212. Taraseviciene-Stewart L, Scerbavicius R, Choe KK et al. 2005. An animal model of autoimmune emphysema. Am J Respir Crit Care Med, 171:734-42.
213. Tjalkens RB, Cook LW, Petersen DR. 1999. Formation and export of the glutathione conjugate of 4-hydroxy-2, 3-E-nonenal (4-HNE) in hepatoma cells. Arch Biochem Biophys, 361:113-19.
214. Tsai SH, Lin-Shiau SY, Lin JK. 1999. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br J Pharmacol, 126:673-80.
215. Tuder RM, Zhen L, Cho CY, et al. 2003. Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade. Am J Respir Cell Mol Biol, 29:88-97.
216. Tuder RM, Yoshida T, Arap W, et al. 2006. State of the art. Cellular and molecular mechanisms of alveolar destruction in emphysema: an evolutionary perspective. Proc Am Thorac Soc, 3:503-10.
217. Tug T, Karatas F, Terzi SM. 2004. Antioxidant vitamins (A, C and E) and malondialdehyde levels in acute exacerbation and stable periods of patients with chronic obstructive pulmonary disease. Clin Invest Med, 27:123-8.
218. Underwood DC, Osborn RR, Bochnowicz S, et al. 2000. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol, 279:L895-902.
219. Underwood DC, Osborn RR, Kotzer CJ, et al. 2000. SB 239063, a potent p3 8 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther, 293:281-8.
220. Uneri C, Sari M, Baglam T, et al. 2006. Effects of vitamin E on cigarette smoke induced oxidative damage in larynx and lung. Laryngoscope, 116:97-100.
221. van Antwerpen L, Theron AJ, Myer MS, et al. 1993. Cigarette smoke-mediated oxidant stress, phagocytes, vitamin C, vitamin E, and tissue injury. Ann N YAcad Sci, 686:53-65.
222. van der Strate BW, Postma DS, Brandsma CA, et al. 2006. Cigarette smoke-induced emphysema: A role for the B cell? Am J Respir Crit Care Med, 173:751-8.
223. van der Vaart H, Koeter GH, PostmaDS, et al. 2005. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 172:465-9.
224. Van Schooten FJ, Besaratinia A, De Flora S, et al. 2002. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol Biomarkers Prev, 11:167-75.
225. Vincent SH, Painter SK, Luffer-Atlas D, et al. 1997. Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys. Drug Metab Dispos, 25:932-9.
226. Voelkel NF, Coll CD. 2003. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Eur Respir J Suppl, 46:28s-32s.
227. Wang RD, Tai H, Xie C, et al. 2003. Cigarette smoke produces airway wall remodeling in rat tracheal explants. Am J Respir Crit Care Med, 168:1232-6.
228. Weathington NM, van Houwelingen AH, Noerager Bl), et al. 2006. A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation. Nat Med, 12:317-23.
229. Wright JL, Farmer SG, Churg A. 2002. Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs. Am J Respir Crit Care Med, 166:954-60.
230. Wright JL, Churg A. 2006. Advances in the pathology of COPD. Histopathology, 49:1-9.
231. Yang SR, Chida AS, Bauter MR, et al. 2006. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am J Physiol Lung Cell Mol Physiol, 291:L46-57.
232. Yoshida M, Korfhagen TR, Whitsett JA. 2001. Surfactant protein D regulates NF-kappa B and matrix metalloproteinase production in alveolar macrophages via oxidant-sensitive pathways. J Immunol, 166:7514-19.
233. Young RP, Hopkins R, Black PN, et al. 2006. Functional variants of antioxidant genes in smokers with COPD and in those with normal lung function. Thorax, 61:394-9.
234. Zandvoort A, Postma DS, Jonker MR, et al. 2006. Altered expression of the Smad signalling pathway: implications for COPD pathogenesis. Eur Respir J, 28:533-41.